Major Events - Chuangsheng Group-B (06628) announced updated efficacy data for osemitamab triple therapy as a first-line treatment for gastric or gastroesophageal junction adenocarcinoma at ESMO Asia [1] - Strength Development (01277) plans to acquire 100% equity of Taiyuan Shidi for approximately 384 million yuan and acquire Dongzhimen property for a total of 86.33 million yuan [1] - Innovent Biologics (01801) completed a global strategic collaboration with Takeda Pharmaceutical and issued 6.9138 million shares under general authorization [1] - Ascentage Pharma-B (06855) received FDA and EMA approval for global registration of a Phase III clinical trial for Nilotinib as a first-line treatment for Ph+ ALL [1] - Baiao Saitou-B (02315) announced that its business partner IDEAYA received IND approval from the FDA for IDE034 [1] - Jinfang Pharmaceutical-B (02595) initiated a registration clinical trial for GFH375, the world's first oral KRAS G12D inhibitor in a controlled chemotherapy Phase III study [1] - Xixiangfeng Group (02473) signed a business cooperation agreement with Hello Car Rental to develop car rental services in designated cities under a "co-branded store" model [1] - International Commercial Settlement (00147) signed a computer chip sales agreement with Hong Kong Antarctic Light to seize growth opportunities in the IC chip market [1] - CSPC Pharmaceutical Group (01093) received clinical trial approval in the U.S. for a GLP-1/GIP receptor dual agonist injection [1] - MIRXES-B (02629) plans to collaborate with Crystal Technology to build an AI-enabled integrated "diagnosis and treatment" research and industrialization platform [1] - Zhengtong Automobile (01728) intends to invest approximately 816 million yuan to acquire Xiamen Xinda 4S dealership and automotive sales and export business [1] - Guorui Life (00108) plans to acquire 78.3% of Beijing Chunyu Tianxia Software for 269 million yuan [1] - Innovent Biologics (01801) successfully included seven innovative products (including new indications) in the 2025 National Medical Insurance Drug List [1] - Peijia Medical-B (09996) had its registration application for the TaurusNXT® "non-aldehyde cross-linked" transcatheter aortic valve replacement system accepted by the National Medical Products Administration [1] - Fosun Pharma (02196) had new drugs included in the National Medical Insurance Directory and commercial insurance innovative drug directory [1] - Junshi Biosciences (01877) had Tuoyi® new indications and Junshida® included in the National Medical Insurance Directory [1] - Valiant Biotech-B (09887) presented clinical data for LBL-034 at the 67th ASH Annual Meeting [1] - Canfite BioPharma (09926) had all approved indications for five marketed drugs successfully included in the latest National Medical Insurance Drug List [1] - Fuhong Hanlin (02696) had Fuzhuoning® (Citrus Acid Vovizili Capsules) included in the National Medical Insurance Drug List [1] - Green Leaf Pharmaceutical (02186) successfully included five new products in the 2025 National Medical Insurance Drug List or commercial insurance innovative drug directory [1] - Yinnuo Pharmaceutical-B (02591) had its core products included in the National Medical Insurance Drug List [1] Operating Performance - Poly Real Estate Group (00119) reported a contract sales amount of approximately 47.7 billion yuan for the first 11 months, a year-on-year decrease of 8.45% [2] - GAC Group (02238) reported November automobile sales of approximately 179,700 units, a year-on-year decline of 9.72% [2] - Xiehe New Energy (00182) reported an equity power generation of 697.23 GWh in November, a year-on-year increase of 7.77% [2]

Group 1 - The company, 力量山西, has agreed to acquire 100% equity of 太原实地 from 遵义实地 for a total price of RMB 384,000,000, with a remaining payable amount of RMB 130,266,000 after offsetting the amounts already paid for the property by 2025 [1] - A share transfer agreement has been established between 力量山西 and 遵义实地 regarding the acquisition of 太原实地 [1] - 力量秦皇岛 has entered into a debt repayment agreement with 广东实地 and 北京实地, which includes the acquisition of properties located at 东直门, with a total cost of RMB 86,330,000 for two properties [1]

Group 1 - The company has entered into a sixth supplemental agreement regarding the property transfer, terminating the rights and responsibilities under the 2022 property purchase agreement for properties not yet registered for transfer [1] - The company will acquire 100% equity of Taiyuan Real Estate from Zunyi Real Estate for a total consideration of RMB 384 million, with a remaining balance of RMB 130 million payable after offsetting amounts already paid [1] - The company has agreed to purchase two properties located in Dongzhimen, Beijing, for a total of RMB 86.33 million, with net payable amounts after tax and debt offsets totaling RMB 56.89 million [2] Group 2 - As of the announcement date, the company has paid RMB 803 million for the acquisition of further adjusted target properties for 2024, but the registration process is not yet complete [3] - The company is actively seeking suitable assets to replace the delayed registration of the 2024 properties and has secured the acquisition of 100% equity of Taiyuan Real Estate as a safeguard [3] - The Dongzhimen properties are considered high-quality assets with strong capital appreciation potential, aligning with the company's strategic goals [3]

Group 1 - The company has entered into a sixth supplemental agreement regarding the property transfer, terminating the rights and responsibilities under the 2022 property purchase agreement for properties not yet registered for transfer [1] - The company will acquire 100% equity of Taiyuan Real Estate from Zunyi Real Estate for a total consideration of RMB 384 million, with a balance of RMB 130 million payable after offsetting amounts already paid for properties [1] - The company has agreed to purchase two properties located in Dongzhimen, Beijing, for a total of RMB 86.33 million, with net payable amount after tax and debt offsets being RMB 56.89 million [2] Group 2 - As of the announcement date, the company has paid RMB 803 million for the acquisition of further adjusted target properties for 2024, but the registration process for these properties is still incomplete [3] - The company is actively seeking suitable assets to replace the delayed registration of the 2024 properties and has secured the acquisition of 100% equity of Taiyuan Real Estate [3] - The Dongzhimen properties are considered high-quality assets with strong capital appreciation potential, aligning with the company's strategic goals [3]

Group 1 - The company announced a sixth supplemental agreement regarding the sale of properties, terminating the rights and responsibilities related to unsold properties as of the effective date of the agreement [1] - The company agreed to acquire 100% equity of Taiyuan Shidi from Zunyi Shidi for a total consideration of RMB 384 million, with a remaining balance of approximately RMB 130 million after offsetting amounts already paid [1] - A share transfer agreement was established between the company and Zunyi Shidi for the acquisition of Taiyuan Shidi [1] Group 2 - The company entered into a debt repayment agreement involving the acquisition of Dongzhimen properties, with a total consideration of RMB 86.33 million for two properties [2] - The agreement includes provisions for tax liabilities and debts to be paid by the company on behalf of Beijing Shidi, totaling RMB 1.105 million and RMB 4.89 million respectively [2] - After deducting the aforementioned amounts, the net payable amount for the Dongzhimen properties is RMB 56.89 million, which will be offset against 2024 payables [2]

茲提述本公司日期為二零二二年五月二日、二零二二年七月十二日、二零二三年 十二月一日、二零二三年十二月十二日、二零二四年二月七日、二零二四年六月 三日、二零二四年六月六日、二零二四年九月六日、二零二四年十一月四日、二零 二四年十一月十二日及二零二五年一月十三日之公告（「該等公告」）及本公司日期 為二零二二年九月三十日、二零二四年二月二十一日、二零二四年十一月二十五 日及二零二四年十二月十九日之通函（「該等通函」）。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 (於開曼群島註冊成立的有限公司) （股份代號：1277） Kinetic Development Group Limited 力量發展集團有限公司 須予披露及關連交易 收購太原實地 及 關連交易 收購東直門物業 獨立董事委員會及獨立股東的獨立財務顧問 緒言 太原實地收購事項的背景 1 於二零二二年四月二十九日，原賣方與本公司間接全資附屬公司力量秦皇島簽訂 二零二二年物業購買協議，據此，原賣方同 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 力量發展集團有限公司 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01277 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 8,430,000,000 | | 0 | | 8,430,000,000 | | 增加 / 減少 (-) | | | 0 | | 0 | | | | 本月底結存 | | | 8,430,000,000 | | 0 | | 8,430,000,000 | 第 2 頁 共 10 頁 v 1.1.1 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | ...

Group 1 - Coal stocks have become active again, with notable price increases for several companies [1] - China Coal Energy (01898.HK) rose by 4.01%, reaching HKD 11.93 [1] - Power Development (01277.HK) increased by 3.16%, trading at HKD 1.63 [1] - Yanzhou Coal Mining (01171.HK) saw a rise of 2.8%, priced at HKD 11.38 [1] - China Shenhua Energy (01088.HK) experienced a smaller increase of 0.87%, now at HKD 41.62 [1]

Core Viewpoint - The coal sector is experiencing a rise in stock prices, driven by expectations of tightening supply and increased demand during the winter heating season [1] Group 1: Stock Performance - Several coal stocks have seen significant gains, with Strength Development (01277) up 5.19% to HKD 1.62, Yida Commodity (01733) up 4.6% to HKD 0.91, China Coal Energy (601898) (01898) up 2.63% to HKD 11.71, and China Shenhua (601088) (01088) up 1.3% to HKD 41.98 [1] Group 2: Market Dynamics - According to Shenwan Hongyuan, the maintenance of the Daqin Railway (601006) has concluded, leading to a month-on-month increase in coal input, although it remains low year-on-year [1] - The central safety production assessment team will fully enter major production areas in November, indicating a tightening safety supervision situation, which is expected to reinforce market expectations for supply constraints [1] - It is anticipated that after adjustments, thermal coal prices will rise due to increased freight costs and the seasonal demand for winter heating [1] Group 3: Dividend Trends - Most coal companies continue to show a strong willingness to distribute high dividends, with six listed coal companies announcing interim dividend plans, including China Shenhua, Shanxi Coking Coal (000983), Shaanxi Coal and Chemical Industry (601225), Shanghai Energy (600508), Yanzhou Coal Mining (600188), and China Coal Energy [1] Group 4: Investment Sentiment - In the context of global political and economic uncertainty and domestic expectations for economic stability, investment behavior in the coal sector is experiencing emotional fluctuations [1] - The coal sector possesses both cyclical and dividend attributes, with current low holdings indicating that the fundamentals have reached a turning point, suggesting it is an opportune time for investment [1]

Group 1 - Coal stocks continue to rise, with notable increases in share prices for several companies [1] - Strength Development (01277.HK) increased by 5.19%, reaching HKD 1.62 [1] - Yida Commodity (01733.HK) rose by 4.6%, reaching HKD 0.91 [1] - China Coal Energy (01898.HK) saw a 2.63% increase, reaching HKD 11.71 [1] - China Shenhua Energy (01088.HK) increased by 1.3%, reaching HKD 41.98 [1]